News2020-05-23T14:50:18+00:00

Read Our Recent News

NanoMab Submits a request to the MHRA to commence a Phase 2 Clinical Study to investigate PD-L1 expression using its NM-01 product as a tool for non-invasive in vivo imaging

London, September 9th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had submitted a request to the MHRA for authorisation for a Phase II Clinical Study Protocol for its NM-01 product. The study will investigate the assessment of programmed death ligand 1 (PD-L1) expression using 99mTc-NM-01 as a SPECT/CT radiotracer and its correlation to PD-L1 expression results based on routine immunohistochemical (IHC) testing in biopsy diagnostic specimens. The study will be carried out [...]

September 10th, 2020|

NanoMab is pleased to announce its collaboration in the EPSRC Programme for Next Generation Imaging and Therapy with Radionuclides (MITHRAS).

NanoMab is pleased to announce its collaboration in the EPSRC Programme for Next Generation Imaging and Therapy with Radionuclides (MITHRAS). London, June 5th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, is pleased to announce that it is participating as an Industrial Partner in the EPSRC Programme for Next Generation Imaging and Therapy with Radionuclides (MITHRAS). The Programme, led by Phil Blower (Professor of Imaging Chemistry at King’s College, London) has been awarded £6 million from the [...]

June 15th, 2020|

NanoMab Enters into Agreement with University Hospital Aachen to initiate a Cancer Therapy Programme utilising next generation NM-02 radiopharmaceutical product.

NanoMab Enters into Agreement with University Hospital Aachen to initiate a Cancer Therapy Programme utilising next generation NM-02 radiopharmaceutical product. Translational Programme established for FIH late stage HER2 positive breast cancer in Q4 2020.   London, May 20th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced a collaboration with University Hospital Aachen to initiate a cancer therapy programme to bring a novel radiopharmaceutical product to patients with HER2 positive breast cancer. The programme will [...]

May 20th, 2020|

NanoMab appoints Paul Edwards as CEO and sets up in UK in preparation for European clinical trial programme

NanoMab appoints Paul Edwards as CEO and sets up in UK in preparation for  European clinical trial programme Precision oncology therapeutics company moves centre of operations from China London, April 28, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies via the development of next generation radiopharmaceuticals, today announced a number of key management changes. The company has also established a UK subsidiary office and moved its centre of operations as it prepares to start clinical trials for [...]

April 28th, 2020|

NanoMab Announces First Breast Cancer Patient Dosed in FIH of 99mTc-NM-02

Date: Aug 13th, 2019 NanoMab Announces First Breast Cancer Patient Dosed in FIH of 99mTc-NM-02 Shanghai, China, August 13th, 2019. NanoMab today announced dosing of the first patients for its FIH trial of 99mTc-NM-02 in patients with breast cancer at SGH. 99mTc-NM-02 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of HER2 expression in patients before or during HER2 targeted treatment

August 13th, 2019|

NanoMab To Initiate FIH for 99mTc-NM-02 at SGH

Date: Aug 1st, 2019 NanoMab To Initiate FIH for 99mTc-NM-02 at SGH Shanghai, China, August 1st, 2019. NanoMab announced that it has decided to initiate FIH with 99mTc-NM-02, which is the company’s breast cancer program. The kick off meeting was held at Shanghai General Hospital (SGH). The primary objective of this study is to evaluate safety, tolerability and pharmacokinetics of 99mTc-NM-02. 99mTc-NM-02 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of HER2 expression in patients [...]

August 1st, 2019|

Contact Us With Any Questions

Please do not hesitate to get in touch with any questions.

CONTACT US